title: Gastric remnant cancer patients had a better prognosis than upper-third gastric cancer patients in a case-control study after surgical treatment.
abstract: BACKGROUND
  The aim was to compare the clinicopathological features and prognostic outcomes of gastric remnant carcinoma patients with those of patients with upper-third gastric cancer.
  
  
  METHODS
  Clinical data extracted from 112 gastric remnant carcinomas and 367 upper-third gastric cancer patients were analyzed to explore the clinicopathologic differences between two groups. After radical resection, prognostic difference between them was evaluated through a 1:2 matched case-control study.
  
  
  RESULTS
  The pattern of gastric remnant carcinomas showed a male predominance. Undifferentiated type histology, depth at T4 stage and distant metastases were more frequent in gastric remnant carcinomas than in upper-third gastric cancers (P <0.05). The radical resectability of gastric remnant carcinomas was lower and the multi-visceral resectabilitiy was relatively higher than the other group (P = 0.00). Gastric remnant carcinomas trended to have a higher incidence of metastases to either mesojejunum or lower mediastinal lymph nodes than upper-third gastric cancers, but patient survival was not significantly different. In the case-control study, gastric remnant carcinomas had a better prognosis than upper-third gastric cancers after radical resection when the clinicopathologic features and surgical treatment were matched.
  
  
  CONCLUSIONS
  Although there was no significant prognostic distinction between gastric remnant carcinomas and upper-third gastric cancer, after radical surgical treatment, patients with the former had an even better prognosis.
authors: Fangxuan
authors: F
authors: Li
authors: Rupeng
authors: R
authors: Zhang
authors: Han
authors: H
authors: Liang
authors: Jichuan
authors: J
authors: Quan
authors: Hui
authors: H
authors: Liu
authors: Hui
authors: H
authors: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018279:Carcinoma, Signet Ring Cell / Q000601:surgery; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D002681:China / Q000453:epidemiology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy / Q000379:methods; D018530:Gastric Stump / Q000473:pathology / Q000601:surgery*; D005763:Gastroenterostomy / Q000379:methods; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D017671:Platinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D017678:Sex Distribution; D012737:Sex Factors; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery*
chemical_list: D017671:Platinum Compounds; D005472:Fluorouracil